Formation of dsRNA by-products during in vitro transcription can be reduced by using low steady-state levels of UTP
Introduction: Exogeneous messenger ribonucleic acid (mRNA) can be used as therapeutic and preventive medication. However, during the enzymatic production process, commonly called in vitro transcription, by-products occur which can reduce the therapeutic efficacy of mRNA. One such by-product is doubl...
Main Authors: | Thomas Ziegenhals, Ronja Frieling, Philipp Wolf, Katharina Göbel, Stina Koch, Mia Lohmann, Markus Baiersdörfer, Stephanie Fesser, Ugur Sahin, Andreas N. Kuhn |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2023-12-01
|
Series: | Frontiers in Molecular Biosciences |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fmolb.2023.1291045/full |
Similar Items
-
The potential of N2-modified cap analogues for precise genetic manipulation through mRNA engineering
by: Karol Kurpiejewski, et al.
Published: (2024-02-01) -
Ribozyme Assays to Quantify the Capping Efficiency of In Vitro-Transcribed mRNA
by: Irena Vlatkovic, et al.
Published: (2022-01-01) -
CleanCap M6 inhibits decapping of exogenously delivered IVT mRNA
by: Zachary F. Mandell, et al.
Published: (2025-03-01) -
Advancing mRNA technologies for therapies and vaccines: An African context
by: Dylan Kairuz, et al.
Published: (2022-10-01) -
The expanding role of cap-adjacent modifications in animals
by: Eleanor Bellows, et al.
Published: (2024-10-01)